Tesamorelin Dosing Protocol: Injection, Nasal Spray, Reconstitution & Research (2026)

Tesamorelin Quick Start

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern, raising IGF-1. It is studied for reducing excess visceral abdominal fat in HIV-associated lipodystrophy, and more broadly in GH-axis and body-composition research.

Quick reference Clinical-trial data

Class

GHRH analog

Formats

Vial (SubQ) · Nasal spray

Action

Pulsatile GH release → IGF-1

Schedule shape

Once daily

Vial size

10 mg

This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.

Tesamorelin Dosing Protocols

The injectable (subcutaneous) and nasal-spray formats are documented as two separate protocols. The reference dose comes from the approved indication (2 mg once daily, subcutaneous). This is shown as research context, not a personal dosing recommendation.

Injection — Subcutaneous

Reconstituted 10 mg vial, U-100 insulin syringe.

Band	Per dose	Frequency
Reference	2 mg	Once daily

10 mg + 2 mL BAC → 5 mg/mL · 2 mg = 0.4 mL = 40 units

Nasal Spray

Pre-mixed nasal spray, ready to use.

Band	Per dose	# of sprays	Frequency
Reference	2 mg	10 sprays	Once daily

Each 0.1 mL spray delivers 0.2 mg (200 mcg)

The approved Tesamorelin dose is 2 mg/day — a milligram-range dose. The spray uses a concentrated 5 mL fill (0.2 mg/spray), so 2 mg ≈ 10 sprays; the injection is the more compact route. GH secretagogues are commonly researched with bedtime, empty-stomach timing.

Tesamorelin Reconstitution Guide

Tesamorelin ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use.

Injection

BAC	Conc.	2 mg
2 mL	5 mg/mL	0.4 mL · 40 u
1 mL	10 mg/mL	0.2 mL · 20 u

Units are U-100 syringe units.

Reconstitution steps

Inspect the vial. Confirm label and intact powder.
Wipe the stoppers. Alcohol swab on both vials.
Draw BAC water. 2 mL into the injectable vial.
Inject down the wall. Release water slowly down the inside wall, not onto the powder.
Swirl, do not shake. Roll gently until clear.
Refrigerate. Store at 2–8 °C; do not freeze.

How to use the nasal spray

Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
Between uses. Wipe the tip, recap, and refrigerate.

How Tesamorelin Works

Tesamorelin binds GHRH receptors on the pituitary and stimulates the synthesis and pulsatile release of endogenous growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). Because it works upstream — prompting the body's own GH pulses rather than supplying GH directly — the GH rise follows a more physiologic pattern. In its approved indication it reduces visceral adipose tissue.

GHRH agonism

Stimulates pituitary GH synthesis and release.

Pulsatile GH

Promotes natural GH pulses rather than constant exogenous GH.

Visceral fat

Approved effect: reduction of visceral adipose tissue.

IGF-1 rise

Downstream IGF-1 increases; monitored as a safety/effect marker.

Who Should Avoid Tesamorelin

Active malignancy

Contraindicated; GH/IGF-1 elevation is a concern with active cancer.

Pregnancy

Contraindicated in the approved labeling.

Disrupted pituitary/HPA axis

Pituitary disease or hypophysectomy affects the GHRH response.

Diabetes / glucose issues

GH elevation can raise blood glucose; monitor closely.

Tesamorelin Side Effects & Safety

Injection-site reactions

The most commonly reported effect in trials; rotate sites.

Arthralgia / fluid retention

Joint pain, swelling, and edema are reported, consistent with GH-axis activity.

Glucose effects

GH elevation can worsen insulin resistance; monitor blood sugar.

IGF-1 elevation

Tracked as a safety marker; sustained high IGF-1 warrants dose review.

Timeline & What to Monitor

Timeframe	Commonly tracked	Notes
Week 1–2	Injection-site tolerance, fluid retention	Early GH-axis effects appear here.
Week 4–8	IGF-1, glucose	IGF-1 is the primary biochemical marker; check glucose.
Month 3–6	Visceral fat / body composition	The approved endpoint develops over months.

Clinical Evidence Context

Approval trials

Phase 3 trials supported approval for reducing visceral fat in HIV-associated lipodystrophy.

NAFLD research

Studied for liver-fat reduction in subsequent research.

GH-axis marker

IGF-1 response is well characterized as the pharmacodynamic readout.

Boundary

Use outside the approved indication is off-label/research context.

Storage & Handling

State	Storage	Notes
Lyophilized (powder)	−20 °C long-term; fridge short-term	More stable than reconstituted solution.
Reconstituted (liquid)	2–8 °C	Use within ~3–4 weeks; do not freeze.
Appearance	Clear, colorless	Discard cloudy or particulate solutions.

Mistakes & Troubleshooting

Too many sprays feel impractical. The 2 mg dose is milligram-range; the injection is the compact route. The spray needs ~10 sprays.
Wrong BAC volume. Recalculate concentration; injection assumes 2 mL, spray assumes 5 mL.
Fluid retention / joint pain. Common GH-axis effects; review dose with a clinician if persistent.
Left out overnight. Treat reconstituted solution as compromised and discard.

Tesamorelin vs Other GH Secretagogues

Feature	Tesamorelin	GHRP-class peptides
Class	GHRH analog	Ghrelin-receptor / GHRP
Action	Stimulates pituitary GHRH receptor	Acts via ghrelin receptor to pulse GH

Blood Tests & Monitoring

Marker	Why	Timing
IGF-1	Primary pharmacodynamic and safety marker for GH-axis activity	Baseline + periodic
Fasting glucose / HbA1c	GH elevation can affect glucose handling	Baseline + periodic
CMP	General safety screen	Baseline

Frequently Asked Questions

What is Tesamorelin?

A stabilized GHRH analog that stimulates natural pulsatile GH release. It is studied for reducing visceral fat in HIV-associated lipodystrophy and more broadly in GH-axis research.

How is the injection dosed vs the nasal spray?

Separate protocols. The reference dose is 2 mg once daily subcutaneous. Because 2 mg is milligram-range, the spray uses a concentrated 5 mL fill (0.2 mg/spray), so 2 mg ≈ 10 sprays — the injection is the more compact route.

How is Tesamorelin reconstituted?

For injection, 10 mg in 2 mL BAC water gives 5 mg/mL, so 2 mg = 0.4 mL = 40 units. The spray ships pre-mixed and delivers 0.2 mg per spray.

What should be monitored?

IGF-1 is the primary marker, along with glucose. Discuss baseline and periodic labs with a clinician.

Is this page medical advice?

No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.

References

Falutz J, et al. Tesamorelin for reduction of visceral adipose tissue (Phase 3). N Engl J Med / J Clin Endocrinol Metab (2010).
Stanley TL, et al. Tesamorelin and liver fat (NAFLD). Lancet HIV / JAMA (2019).
World Anti-Doping Agency. Prohibited List 2025 (GHRH analogs).